{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:53:00Z","timestamp":1793213580262,"version":"4.5.0"},"reference-count":164,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CIMB"],"abstract":"<jats:p>Lipid hormone imbalances involving glucocorticoids, thyroid hormones (THs), and sex hormones have widespread metabolic consequences, contributing to the global increase in obesity and insulin resistance. This review examines the complex role of disrupted lipid hormone pathways in the development of metabolic disorders, particularly metabolic dysfunction-associated steatotic liver disease (MASLD). Endocrine disorders such as hypercortisolism, hypothyroidism, and polycystic ovary syndrome (PCOS) are closely linked to MASLD through shared metabolic pathways. Mechanisms include glucocorticoid-induced gluconeogenesis and lipolysis, impaired lipid clearance in hypothyroidism, and the hyperandrogenism-induced downregulation of hepatic low-density lipoprotein (LDL) receptors. PCOS-related factors\u2014such as central obesity, adipocyte hypertrophy, low adiponectin levels, and genetic predisposition\u2014further promote hepatic steatosis. Thyroid dysfunction may also impair the hepatic deiodination of T4, contributing to lipid accumulation and inflammation. Given the overlapping pathophysiology among endocrine, hepatic, and reproductive disorders, multidisciplinary collaboration is essential to optimize diagnosis, treatment, and long-term cardiometabolic outcomes.<\/jats:p>","DOI":"10.3390\/cimb47070565","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T13:33:27Z","timestamp":1752845607000},"page":"565","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Lipid Hormones at the Intersection of Metabolic Imbalances and Endocrine Disorders"],"prefix":"10.3390","volume":"47","author":[{"given":"Maria-Zinaida","family":"Dobre","sequence":"first","affiliation":[{"name":"Department of Biochemistry, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdana","family":"Virgolici","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruxandra","family":"Cioarc\u0103-Nedelcu","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s40273-014-0243-x","article-title":"The Epidemiology of Obesity: A Big Picture","volume":"33","author":"Hruby","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.3350\/cmh.2022.0367","article-title":"MAFLD: How is it different from NAFLD?","volume":"29","author":"Gofton","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/j.jhep.2023.07.021","article-title":"Can we use old NAFLD data under the new MASLD definition?","volume":"80","author":"Song","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Von-Hafe, M., Borges-Canha, M., Vale, C., Leite, A., Neves, J.S., Carvalho, D., and Leite-Moreira, A. (2022). Nonalcoholic Fatty Liver Disease and Endocrine Axes\u2014A Scoping Review. Metabolites, 12.","DOI":"10.3390\/metabo12040298"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jhep.2023.08.030","article-title":"Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistance","volume":"79","author":"Hutchison","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/oby.2009.419","article-title":"Environmental endocrine disruptors promote adipogenesis in the 3T3-L1 cell line through glucocorticoid receptor activation","volume":"18","author":"Sargis","year":"2010","journal-title":"Obesity"},{"key":"ref_9","unstructured":"Richard, A.J., White, U., Elks, C.M., and Stephens, J.M. (2025, March 20). Adipose Tissue: Physiology to Metabolic Dysfunction, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK555602\/."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ecl.2013.10.005","article-title":"Mechanisms of glucocorticoid-induced insulin resistance: Focus on adipose tissue function and lipid metabolism","volume":"43","author":"Geer","year":"2014","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"382","DOI":"10.22363\/2313-0245-2022-26-4-382-395","article-title":"Polycystic ovary syndrome and obesity: A modern paradigm","volume":"26","author":"Khamoshina","year":"2022","journal-title":"Rudn. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"101369","DOI":"10.1016\/j.jhepr.2025.101369","article-title":"Thyroid dysfunction in MASLD: Results of a nationwide study","volume":"7","author":"Yuan","year":"2025","journal-title":"JHEP Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"11336","DOI":"10.1073\/pnas.1605246113","article-title":"Acute stress enhances heterodimerization and binding of corticosteroid receptors at glucocorticoid target genes in the hippocampus","volume":"113","author":"Mifsud","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3803\/EnM.2017.32.2.180","article-title":"Glucocorticoid-Induced Diabetes Mellitus: An Important but Overlooked Problem","volume":"32","author":"Suh","year":"2017","journal-title":"Endocrinol. Metab."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s13679-024-00556-1","article-title":"Role of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"13","author":"Polyzos","year":"2024","journal-title":"Curr. Obes. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3803\/EnM.2024.1951","article-title":"Glucocorticoid-Induced Hyperglycemia: A Neglected Problem","volume":"39","author":"Cho","year":"2024","journal-title":"Endocrinol. Metab."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Kang, D., Zhao, D., Ryu, S., Guallar, E., Cho, J., Lazo, M., Shin, H., Chang, Y., and Sung, E. (2020). Perceived stress and non-alcoholic fatty liver disease in apparently healthy men and women. Sci. Rep., 10.","DOI":"10.1038\/s41598-019-57036-z"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.metabol.2011.06.012","article-title":"The effects of glucocorticoids on adipose tissue lipid metabolism","volume":"60","author":"Peckett","year":"2011","journal-title":"Metabolism"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ahmed, B., Sultana, R., and Greene, M.W. (2021). Adipose tissue and insulin resistance in obesity. Biomed. Pharmacother., 137.","DOI":"10.1016\/j.biopha.2021.111315"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1365-2265.2009.03712.x","article-title":"HPA axis functioning in relation to body fat distribution","volume":"72","author":"Rutters","year":"2010","journal-title":"Clin. Endocrinol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1196\/annals.1367.009","article-title":"The hypothalamic-pituitary-adrenal axis activity in obesity and the metabolic syndrome","volume":"1083","author":"Pasquali","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.cell.2012.02.017","article-title":"Mechanisms for insulin resistance: Common threads and missing links","volume":"148","author":"Samuel","year":"2012","journal-title":"Cell"},{"key":"ref_23","first-page":"545","article-title":"Interaction between free fatty acids and glucose metabolism","volume":"5","author":"Boden","year":"2002","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.bbadis.2013.05.029","article-title":"Deconstructing the roles of glucocorticoids in adipose tissue biology and the development of central obesity","volume":"1842","author":"Lee","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/0031-9384(92)90351-2","article-title":"Effect of chronic stress and exogenous glucocorticoids on regional fat distribution and metabolism","volume":"52","author":"Walsh","year":"1992","journal-title":"Physiol. Behav."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1210\/jc.2003-031157","article-title":"Glucocorticoids down-regulate glucose uptake capacity and insulin-signaling proteins in omental but not subcutaneous human adipocytes","volume":"89","author":"Lundgren","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1002\/dvdy.708","article-title":"Deciphering adipose development: Function, differentiation and regulation","volume":"253","author":"Guo","year":"2024","journal-title":"Dev. Dyn."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1194\/jlr.R800031-JLR200","article-title":"Adipose triglyceride lipase and the lipolytic catabolism of cellular fat stores","volume":"50","author":"Zechner","year":"2009","journal-title":"J. Lipid Res."},{"key":"ref_29","first-page":"455","article-title":"Glucocorticoid-induced regulation of lipid metabolism","volume":"125","author":"Smith","year":"2010","journal-title":"J. Endocrinol. Metab."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1126\/science.1066285","article-title":"A transgenic model of visceral obesity and the metabolic syndrome","volume":"294","author":"Masuzaki","year":"2001","journal-title":"Science"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1210\/jcem.87.1.8158","article-title":"Cortisol and ACTH response to oral dexamethasone in obesity and effects of sex, body fat distribution, and dexamethasone concentrations: A dose\u2013response study","volume":"87","author":"Pasquali","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"E385","DOI":"10.1152\/ajpendo.00052.2008","article-title":"Lower growth hormone and higher cortisol are associated with greater visceral adiposity in overweight girls","volume":"295","author":"Misra","year":"2008","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_33","first-page":"839","article-title":"A pulse of insulin and dexamethasone stimulates serum leptin in fasting human subjects","volume":"146","author":"Caixas","year":"2002","journal-title":"Eur. J. Endocrinol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1210\/en.2004-0037","article-title":"Glucocorticoids\u2014Food intake, abdominal obesity, and wealthy nations in 2004","volume":"145","author":"Dallman","year":"2004","journal-title":"Endocrinology"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Bavaresco, A., Mazzeo, P., Lazzara, M., and Barbot, M. (2024). Adipose tissue in cortisol excess: What Cushing\u2019s syndrome can teach us?. Biochem. Pharmacol., 223.","DOI":"10.1016\/j.bcp.2024.116137"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"133","DOI":"10.4274\/haseki.galenos.2021.6749","article-title":"The Effect of Chronic Glucocorticoid Exposure on Brown Adipose Tissue in Cushing\u2019s Disease","volume":"59","author":"Selek","year":"2021","journal-title":"Med. Bull. Haseki."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1365-2265.2007.02774.x","article-title":"Increased insulin-stimulated endothelin-1 release is a distinct vascular phenotype distinguishing Cushing\u2019s disease from metabolic syndrome","volume":"66","author":"Setola","year":"2007","journal-title":"Clin. Endocrinol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ecl.2008.06.007","article-title":"Obesity and free fatty acids","volume":"37","author":"Boden","year":"2008","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"728","DOI":"10.2337\/diab.41.6.728","article-title":"Role of glucose transporters in glucocorticoid-induced insulin resistance. GLUT4 isoform in rat skeletal muscle is not decreased by dexamethasone","volume":"41","author":"Haber","year":"1992","journal-title":"Diabetes"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Schernthaner-Reiter, M.H., Wolf, P., Vila, G., and Luger, A. (2021). The interaction of insulin and pituitary hormone syndromes. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.626427"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.2147\/DMSO.S247379","article-title":"Glucocorticoid-induced fatty liver disease","volume":"13","author":"Rahimi","year":"2020","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"E654","DOI":"10.1152\/ajpendo.00453.2006","article-title":"Glucocorticoids produce whole body insulin resistance with changes in cardiac metabolism","volume":"292","author":"Qi","year":"2007","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2337\/dsi23-0013","article-title":"Role of insulin resistance in the development of nonalcoholic fatty liver disease in people with type 2 diabetes: From bench to patient care","volume":"37","author":"Nogueira","year":"2024","journal-title":"Diabetes Spectr."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1210\/er.2003-0031","article-title":"11\u03b2-Hydroxysteroid dehydrogenase type 1: A tissue-specific amplifier of glucocorticoid action","volume":"25","author":"Tomlinson","year":"2004","journal-title":"Endocr. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4314\/ovj.v8i1.13","article-title":"Overexpression of 11\u03b2-hydroxysteroid dehydrogenase 1 in visceral adipose tissue and underexpression of endothelial nitric oxide synthase in the adrenal cortex of dogs with hyperadrenocorticism","volume":"8","author":"Miceli","year":"2018","journal-title":"Open Vet. J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.2147\/DDDT.S285828","article-title":"Selective inhibition of 11\u03b2-hydroxysteroid dehydrogenase type 1 attenuates high-fat diet-induced hepatic steatosis in mice","volume":"15","author":"Li","year":"2021","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Ahmed, A., Rabbitt, E., Brady, T., Brown, C., Guest, P., Bujalska, I.J., Doig, C., Newsome, P.N., Hubscher, S., and Elias, E. (2012). A switch in hepatic cortisol metabolism across the spectrum of non alcoholic fatty liver disease. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0029531"},{"key":"ref_48","first-page":"237","article-title":"Metabolic-associated fatty liver disease and the role of hormones in its aetiopathogenesis","volume":"75","author":"Junik","year":"2024","journal-title":"Endokrynol. Pol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Yang, B., Gong, M., Zhu, X., Yang, Y.L., Li, L.R., Meng, H., and Wang, Y. (2025). Correlation between liver fibrosis in non-alcoholic fatty liver disease and insulin resistance indicators: A cross-sectional study from NHANES 2017\u20132020. Front. Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1514093"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41574-019-0230-6","article-title":"The endocrine function of adipose tissues in health and cardiometabolic disease","volume":"15","author":"Scheja","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Todisco, S., Santarsiero, A., Convertini, P., De Stefano, G., Gilio, M., Iacobazzi, V., and Infantino, V. (2022). PPAR Alpha as a metabolic modulator of the liver: Role in the pathogenesis of nonalcoholic steatohepatitis (NASH). Biology, 11.","DOI":"10.3390\/biology11050792"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.fshw.2023.02.019","article-title":"Dexamethasone potentiates the insulin-induced Srebp-1c expression in primary rat hepatocytes","volume":"12","author":"Zhang","year":"2023","journal-title":"Food Sci. Human Wellness"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsbmb.2015.09.020","article-title":"Hyperinsulinemia caused by dexamethasone treatment is associated with reduced insulin clearance and lower hepatic activity of insulin-degrading enzyme","volume":"155 Pt A","author":"Protzek","year":"2016","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1172\/JCI66062","article-title":"Dexamethasone-induced Kr\u00fcppel-like factor 9 expression promotes hepatic gluconeogenesis and hyperglycemia","volume":"129","author":"Cui","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3109\/10253890.2010.543444","article-title":"Dexamethasone-induced hepatic lipogenesis is insulin dependent in chickens (Gallus gallus domesticus)","volume":"14","author":"Cai","year":"2011","journal-title":"Stress"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.tcb.2011.03.001","article-title":"Bcl-2 proteins in diabetes: Mitochondrial pathways of \u03b2-cell death and dysfunction","volume":"21","author":"Gurzov","year":"2011","journal-title":"Trends Cell Biol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"9601801","DOI":"10.1155\/2018\/9601801","article-title":"Pancreatic beta cell death: Novel potential mechanisms in diabetes therapy","volume":"2018","author":"Rojas","year":"2018","journal-title":"J. Diabetes Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1930261","DOI":"10.1155\/2017\/1930261","article-title":"Oxidative stress in pancreatic beta cell regeneration","volume":"2017","author":"Wang","year":"2017","journal-title":"Oxid. Med. Cell Longev."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1530\/JME-20-0238","article-title":"Dexamethasone induces pancreatic \u03b2-cell apoptosis through upregulation of TRAIL death receptor","volume":"67","author":"Suksri","year":"2021","journal-title":"J. Mol. Endocrinol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.molmet.2019.12.012","article-title":"Glucocorticoid induces human beta cell dysfunction by involving riborepressor GAS5 LincRNA","volume":"32","author":"Esguerra","year":"2020","journal-title":"Mol. Metab."},{"key":"ref_61","first-page":"FF08","article-title":"Dose dependent hepatic and endothelial changes in rats treated with dexamethasone","volume":"9","author":"Kumar","year":"2015","journal-title":"J. Clin. Diagn. Res."},{"key":"ref_62","first-page":"114","article-title":"Establishment of dexamethasone model as a model for metabolic-associated hepatic injury in male Wistar rats","volume":"7","author":"Amer","year":"2024","journal-title":"Delta Univ. Sci. J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"419","DOI":"10.4103\/0253-7613.28209","article-title":"Prevention of dexamethasone- and fructose-induced insulin resistance in rats by SH-01D, a herbal preparation","volume":"38","author":"Shalam","year":"2006","journal-title":"Indian J. Pharmacol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Mahmoud, M.F., Ali, N., Mostafa, I., Hasan, R.A., and Sobeh, M. (2022). Coriander oil reverses dexamethasone-induced insulin resistance in rats. Antioxidants, 11.","DOI":"10.3390\/antiox11030441"},{"key":"ref_65","first-page":"25","article-title":"Biochemical and radiological changes in liver steatosis following mifepristone treatment in patients with hypercortisolism","volume":"8","author":"Parker","year":"2022","journal-title":"AACE Clin. Case Rep."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Bagnato, C.B., Bianco, A., Bonfiglio, C., Franco, I., Verrelli, N., Carella, N., Shahini, E., Zappimbulso, M., Giannuzzi, V., and Pesole, P.L. (2024). Healthy lifestyle changes improve cortisol levels and liver steatosis in MASLD patients: Results from a randomized clinical trial. Nutrients, 16.","DOI":"10.3390\/nu16234225"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e1708","DOI":"10.1210\/clinem\/dgae004","article-title":"DXA-based fat mass with risk of worsening insulin resistance in adolescents: A 9-year temporal and mediation study","volume":"109","author":"Agbaje","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Rigal, S., Casas, B., Kanebratt, K.P., Wennberg Huldt, C., Magnusson, L.U., M\u00fcllers, E., Karlsson, F., Clausen, M., Hansson, S.F., and Leonard, L. (2024). Normoglycemia and physiological cortisone level maintain glucose homeostasis in a pancreas-liver microphysiological system. Commun. Biol., 7.","DOI":"10.1038\/s42003-024-06514-w"},{"key":"ref_69","unstructured":"Radner, G. (2023). Polycystic Ovary Syndrome (PCOS), Gynakol Prax."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Spremovi\u0107 Ra\u0111enovi\u0107, S., Pupovac, M., Andji\u0107, M., Bila, J., Sre\u0107kovi\u0107, S., Gudovi\u0107, A., Draga\u0161, B., and Radunovi\u0107, N. (2022). Prevalence, risk factors, and pathophysiology of nonalcoholic fatty liver disease (NAFLD) in women with polycystic ovary syndrome (PCOS). Biomedicines, 10.","DOI":"10.3390\/biomedicines10010131"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.2147\/DMSO.S362424","article-title":"Current perspectives on nonalcoholic fatty liver disease in women with polycystic ovary syndrome","volume":"15","author":"Wang","year":"2022","journal-title":"Diabetes Metab. Syndr. Obes. Targets Ther."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Liao, B., Qiao, J., and Pang, Y. (2021). Central regulation of PCOS: Abnormal neuronal-reproductive-metabolic circuits in PCOS pathophysiology. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.667422"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Harada, M. (2022). Pathophysiology of polycystic ovary syndrome revisited: Current understanding and perspectives regarding future research. Reprod. Med. Biol., 21.","DOI":"10.1002\/rmb2.12487"},{"key":"ref_74","first-page":"22","article-title":"Hyperandrogenism in women with polycystic ovarian syndrome: Pathophysiology and controversies","volume":"3","author":"Kanbour","year":"2022","journal-title":"Androgens"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"101","DOI":"10.53853\/encr.6.2.484","article-title":"Updated approach to the pathophysiology, classification and genetics of polycystic ovarian syndrome","volume":"6","author":"Orrego","year":"2019","journal-title":"Rev. Colomb. Endocrinol. Diabetes Metab."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Ding, H., Zhang, J., Zhang, F., Zhang, S., Chen, X., Liang, W., and Xie, Q. (2021). Resistance to insulin and elevated level of androgen: A major cause of polycystic ovary syndrome. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.741764"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Petta, S., Ciresi, A., Bianco, J., Geraci, V., Boemi, R., Galvano, L., Magliozzo, F., Merlino, G., Crax\u00ec, A., and Giordano, C. (2017). Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0186136"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"37","DOI":"10.24293\/ijcpml.v27i1.1600","article-title":"Correlation between serum dehydroepiandrosterone sulfate and LDL cholesterol in patients with polycystic ovarian syndrome","volume":"27","author":"Gunawan","year":"2020","journal-title":"Indones. J. Clin. Pathol. Med. Lab."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Zhang, H., Wang, W., Zhao, J., Jiao, P., Zeng, L., Zhang, H., Zhao, Y., Shi, L., Hu, H., and Luo, L. (2023). Relationship between body composition, insulin resistance, and hormonal profiles in women with polycystic ovary syndrome. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.1085656"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"36","DOI":"10.32771\/inajog.v12i1.2031","article-title":"Body composition parameters, adiponectin, leptin and adiponectin\/leptin ratio are correlated with LH\/FSH ratio in women with PCOS but not in women without PCOS","volume":"12","author":"Pratama","year":"2024","journal-title":"Indones. J. Obstet. Gynecol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Recuero, A.M., Gomes, L.G., Maciel, G.A.R., de Mello Malta, F., Salles, A.P.M., Vezozzo, D.C.P., Baracat, E.C., Pinho, J.R.R., Carrilho, F.J., and Stefano, J.T. (2022). NAFLD in Polycystic Ovary Syndrome: Association with PNPLA3 and Metabolic Features. Biomedicines, 10.","DOI":"10.3390\/biomedicines10112719"},{"key":"ref_82","first-page":"310","article-title":"Non-alcoholic fatty liver disease and women\u2019s health","volume":"7","author":"Livzan","year":"2023","journal-title":"Russ. Med. Rev."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"100835","DOI":"10.1016\/j.jhepr.2023.100835","article-title":"Non-alcoholic fatty liver disease in women\u2014Current knowledge and emerging concepts","volume":"5","author":"Eng","year":"2023","journal-title":"JHEP Rep."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"914938","DOI":"10.1155\/2012\/914938","article-title":"NAFLD, Estrogens, and Physical Exercise: The Animal Model","volume":"2012","author":"Lavoie","year":"2012","journal-title":"J. Nutr. Metab."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"bqaa134","DOI":"10.1210\/endocr\/bqaa134","article-title":"NAFLD and NASH in Postmenopausal Women: Implications for Diagnosis and Treatment","volume":"161","author":"DiStefano","year":"2020","journal-title":"Endocrinology"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Zhao, C., Shi, J., Shang, D., Guo, M., Zhou, C., and Zhao, W. (2023). Protective effect of phytoestrogens on nonalcoholic fatty liver disease in postmenopausal women. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1237845"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"108024","DOI":"10.1016\/j.maturitas.2024.108024","article-title":"Menopause and metabolic dysfunction-associated steatotic liver disease","volume":"186","author":"Polyzos","year":"2024","journal-title":"Maturitas"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.dld.2024.05.003","article-title":"Age at menopause and risk of metabolic dysfunction-associated fatty liver disease: A 14-year cohort study","volume":"56","author":"Kim","year":"2024","journal-title":"Dig. Liver Dis."},{"key":"ref_89","first-page":"822","article-title":"Hormone replacement therapy in menopausal women: Risk factor or protection to nonalcoholic fatty liver disease?","volume":"18","author":"Florentino","year":"2019","journal-title":"Ann. Hepatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.12998\/wjcc.v11.i6.1236","article-title":"Sex dimorphism and metabolic profiles in management of metabolic-associated fatty liver disease","volume":"11","author":"Monleon","year":"2023","journal-title":"World J. Clin. Cases"},{"key":"ref_91","first-page":"2387","article-title":"Nonalcoholic fatty liver disease: A major challenge in type 2 diabetes mellitus (Review)","volume":"20","author":"Bica","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1093\/ejendo\/lvad098","article-title":"The impact of metformin with or without lifestyle modification versus placebo on polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials","volume":"189","author":"Melin","year":"2023","journal-title":"Eur. J. Endocrinol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4103\/2096-2924.268160","article-title":"Therapeutic effect of metformin on patients with polycystic ovary syndrome with normal insulin sensitivity: A retrospective study","volume":"3","author":"Liu","year":"2019","journal-title":"Reprod. Dev. Med."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Riemann, A., Blaschke, M., Jauho-Ghadimi, A., Siggelkow, H., and Gollisch, K.S.C. (2022). Metformin Improves the Hepatic Steatosis Index in Non-Obese Patients with Polycystic Ovary Syndrome. J. Clin. Med., 11.","DOI":"10.3390\/jcm11154294"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/cen.12369","article-title":"GLP-1 analogue, liraglutide, improves liver fibrosis markers in obese women with PCOS and NAFLD","volume":"81","author":"Kahal","year":"2014","journal-title":"Clin. Endocrinol."},{"key":"ref_96","first-page":"e72596","article-title":"Vitamin E and Non-alcoholic Fatty Liver Disease: Investigating the Evidence Through a Systematic Review","volume":"16","author":"Abera","year":"2024","journal-title":"Cureus"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1210\/jc.2009-0870","article-title":"Omega-3 fatty acid supplementation decreases liver fat content in PCOS: A randomized controlled trial","volume":"94","author":"Cussons","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1172\/JCI60047","article-title":"Mechanisms of thyroid hormone action","volume":"122","author":"Brent","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s42255-024-00986-0","article-title":"Metabolic messengers: Thyroid hormones","volume":"6","author":"Sinha","year":"2024","journal-title":"Nat. Metab."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrendo.2018.10","article-title":"Direct effects of thyroid hormones on hepatic lipid metabolism","volume":"14","author":"Sinha","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"19554","DOI":"10.1074\/jbc.M111771200","article-title":"SREBP-1 interacts with thyroid hormone receptor to enhance ACC-alpha transcription","volume":"277","author":"Yin","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"E884","DOI":"10.1152\/ajpendo.90438.2008","article-title":"Hepatic regulation of fatty acid synthase by insulin and T3","volume":"295","author":"Radenne","year":"2008","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1016\/S0021-9258(19)67894-4","article-title":"T3 stimulates and cAMP inhibits malic enzyme gene transcription in chick embryo hepatocytes","volume":"266","author":"Salati","year":"1991","journal-title":"J. Biol. Chem."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"eabh3839","DOI":"10.1126\/scisignal.abh3839","article-title":"Thyroid hormone signaling promotes hepatic lipogenesis via ChREBP","volume":"14","author":"Mendoza","year":"2021","journal-title":"Sci. Signal."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2174\/1874192401105010076","article-title":"Effects of thyroid dysfunction on lipid profile","volume":"5","author":"Rizos","year":"2011","journal-title":"Open Cardiovasc. Med. J."},{"key":"ref_106","first-page":"e0596","article-title":"Thyroid hormone and the liver","volume":"9","author":"Ritter","year":"2024","journal-title":"Hepatol. Commun."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.mce.2014.02.003","article-title":"Thyroid hormone induction of human CYP7A1 in vitro","volume":"388","author":"Angajala","year":"2014","journal-title":"Mol. Cell Endocrinol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1006\/abbi.1995.0061","article-title":"Regulation of LDL receptor and CYP7A1 by thyroid hormone in rat liver","volume":"323","author":"Ness","year":"1995","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1089\/thy.2006.0302","article-title":"Lipoprotein alterations, hepatic lipase activity, and insulin sensitivity in subclinical hypothyroidism","volume":"17","author":"Brenta","year":"2007","journal-title":"Thyroid"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1152\/physrev.00030.2013","article-title":"Thyroid hormone regulation of metabolism","volume":"94","author":"Mullur","year":"2014","journal-title":"Physiol. Rev."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/hep.31296","article-title":"Thyroid hormone signaling and the liver","volume":"72","author":"Ritter","year":"2020","journal-title":"Hepatology"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Yassine, H. (2015). Dyslipidemia: Relationship to Insulin Resistance and Fatty Liver. Lipid Management, Springer.","DOI":"10.1007\/978-3-319-11161-2"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Ramanathan, R., Patwa, S.A., Ali, A.H., and Ibdah, J.A. (2023). Thyroid hormone and mitochondrial dysfunction in MASLD. Cells, 12.","DOI":"10.3390\/cells12242806"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"152850","DOI":"10.4061\/2011\/152850","article-title":"Why can insulin resistance be a consequence of thyroid dysfunction?","volume":"2011","author":"Brenta","year":"2011","journal-title":"J. Thyroid. Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1210\/mend.14.7.0470","article-title":"Thyroid hormone regulation of hepatic genes in vivo","volume":"14","author":"Feng","year":"2000","journal-title":"Mol. Endocrinol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1042\/bj3090913","article-title":"Regulation of PEPCK gene by thyroid hormone","volume":"309","author":"Park","year":"1995","journal-title":"Biochem. J."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"9492","DOI":"10.1016\/S0021-9258(19)83543-3","article-title":"Effect of thyroid hormone on turnover of pyruvate carboxylase and PDH","volume":"254","author":"Weinberg","year":"1979","journal-title":"J. Biol. Chem."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1210\/endo.135.2.8033812","article-title":"Regulation of GLUT2 by thyroid hormone","volume":"135","author":"Weinstein","year":"1994","journal-title":"Endocrinology"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.2337\/diab.43.10.1185","article-title":"Thyroid hormone increases glucose transport in skeletal muscle via GLUT4","volume":"43","author":"Weinstein","year":"1994","journal-title":"Diabetes"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Tanase, D.M., Gosav, E.M., Neculae, E., Costea, C.F., Ciocoiu, M., Hurjui, L.L., Tarniceriu, C.C., and Floria, M. (2020). Hypothyroidism-induced NAFLD: Mechanisms and therapeutic options. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21165927"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/poh2.100","article-title":"Resmetirom and thyroid hormone receptor\u2014Targeted treatment for MASLD","volume":"4","author":"Liu","year":"2025","journal-title":"Portal Hypertens. Cirrhosis."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Kochman, J., Jakubczyk, K., Bargiel, P., and Janda-Milczarek, K. (2021). The influence of oxidative stress on thyroid diseases. Antioxidants, 10.","DOI":"10.3390\/antiox10091442"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Biondi, B. (2024). Subclinical hypothyroidism in patients with obesity and metabolic syndrome. Nutrients, 16.","DOI":"10.3390\/nu16010087"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1089\/thy.2011.0499","article-title":"Interconnections between obesity, thyroid function, and autoimmunity","volume":"23","author":"Duntas","year":"2013","journal-title":"Thyroid"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Chaker, L., Ligthart, S., Korevaar, T.I., Hofman, A., Franco, O.H., Peeters, R.P., and Dehghan, A. (2016). Thyroid function and risk of type 2 diabetes. BMC Med., 14.","DOI":"10.1186\/s12916-016-0693-4"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1136\/gutjnl-2024-332491","article-title":"Association between primary hypothyroidism and metabolic dysfunction-associated steatotic liver disease: An updated meta-analysis","volume":"73","author":"Mantovani","year":"2024","journal-title":"Gut"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1001\/jama.291.2.228","article-title":"Subclinical thyroid disease: Scientific review and guidelines for diagnosis and management","volume":"291","author":"Surks","year":"2004","journal-title":"JAMA"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"5753039","DOI":"10.1155\/2017\/5753039","article-title":"Benefits of Levothyroxine Replacement Therapy on Nonalcoholic Fatty Liver Disease in Subclinical Hypothyroidism Patients","volume":"2017","author":"Liu","year":"2017","journal-title":"Int. J. Endocrinol."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Sheikhi, V., and Heidari, Z. (2022). Association of subclinical hypothyroidism with nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A cross-sectional study. Adv. Biomed. Res., 11.","DOI":"10.4103\/abr.abr_15_21"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.dld.2018.08.012","article-title":"Association of non-alcoholic fatty liver disease with thyroid function: A systematic review and meta-analysis","volume":"50","author":"Guo","year":"2018","journal-title":"Dig. Liver Dis."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jhep.2024.10.018","article-title":"Thyroid hormone receptor-\u03b2 analogues for the treatment of metabolic dysfunction-associated steatohepatitis (MASH)","volume":"82","author":"Ratziu","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.1210\/clinem\/dgad016","article-title":"Impact of thyroid function on the prevalence and mortality of metabolic dysfunction-associated fatty liver disease","volume":"108","author":"Chen","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Somnay, K., Wadgaonkar, P., Sridhar, N., Roshni, P., Rao, N., and Wadgaonkar, R. (2024). Liver fibrosis leading to cirrhosis: Mechanisms and clinical perspectives. Biomedicines, 12.","DOI":"10.3390\/biomedicines12102229"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Chao, G., Zhu, Y., and Bao, Y. (2024). Screening study of liver fibrosis risk in patients with MAFLD. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-74792-9"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Martag\u00f3n, A.J., Lin, J.Z., Cimini, S.L., Webb, P., and Phillips, K.J. (2015). TR agonists reduce steatosis but not insulin resistance in ob\/ob mice. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0122987"},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Wang, X., Wang, L., Geng, L., Tanaki, N., and Ye, B. (2023). Resmetirom ameliorates NASH by suppressing STAT3\/NF-\u03baB. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065843"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"481482","DOI":"10.1155\/2014\/481482","article-title":"The emerging role of TR\u03b11 in cardiac repair: Potential therapeutic implications","volume":"2014","author":"Pantos","year":"2014","journal-title":"Oxid. Med. Cell Longev."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1210\/er.2009-0007","article-title":"Molecular aspects of thyroid hormone actions","volume":"31","author":"Cheng","year":"2010","journal-title":"Endocr. Rev."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.mce.2013.11.015","article-title":"The two major isoforms of thyroid hormone receptor, TR\u03b11 and TR\u03b21, preferentially partner with distinct panels of auxiliary proteins","volume":"383","author":"Schroeder","year":"2014","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_140","first-page":"5958","article-title":"Thyroid hormones and thyroid hormone receptors: Effects of thyromimetics on reverse cholesterol transport","volume":"16","author":"Pedrelli","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1021\/jm021080f","article-title":"Thyroid receptor ligands. 1. agonist ligands selective for the thyroid receptor \u03b21","volume":"46","author":"Liu","year":"2003","journal-title":"J. Med. Chem."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"101122","DOI":"10.1016\/j.molmet.2020.101122","article-title":"Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans","volume":"50","author":"Pafili","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Zhao, M., Xie, H., Shan, H., Zheng, Z., Li, G., Li, M., and Hong, L. (2022). Development of Thyroid Hormones and Synthetic Thyromimetics in Non-Alcoholic Fatty Liver Disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031102"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"e2005","DOI":"10.1210\/clinem\/dgab002","article-title":"Dyslipidemia, Insulin Resistance, Ectopic Lipid Accumulation, and Vascular Function in Resistance to Thyroid Hormone \u03b2","volume":"106","author":"Moran","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.beem.2015.07.007","article-title":"Resistance to thyroid hormone due to defective thyroid receptor alpha","volume":"29","author":"Moran","year":"2015","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.apsb.2024.07.025","article-title":"Drug discovery targeting thyroid hormone receptor \u03b2 (THR\u03b2) for the treatment of liver diseases and other medical indications","volume":"15","author":"Wang","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1021\/jm4019299","article-title":"Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a highly selective thyroid hormone receptor \u03b2 agonist in clinical trials for the treatment of dyslipidemia","volume":"57","author":"Kelly","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_148","first-page":"67","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"T Rados. N. Engl. J. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"7075","DOI":"10.1021\/jm800824d","article-title":"Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs","volume":"51","author":"Boyer","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Tang, Q., Zeng, M., Chen, L., and Fu, N. (2022). Targeting Thyroid Hormone\/Thyroid Hormone Receptor Axis: An Attractive Therapy Strategy in Liver Diseases. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.871100"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1073\/pnas.0705286104","article-title":"The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans","volume":"105","author":"Berkenstam","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1074-5521(98)90168-5","article-title":"A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor","volume":"5","author":"Chiellini","year":"1998","journal-title":"Chem. Biol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.pharmthera.2011.04.003","article-title":"Thyromimetics: A journey from bench to bed-side","volume":"131","author":"Tancevski","year":"2011","journal-title":"Pharmacol. Ther."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.dld.2022.11.020","article-title":"Thyroid hormones and MAFLD: Mediated by obesity and metabolic disorders","volume":"55","author":"Fan","year":"2023","journal-title":"Dig. Liver Dis."},{"key":"ref_155","unstructured":"FDA (2025, March 20). Roadmap to Reducing Animal Testing in Preclinical Safety Studies, Available online: https:\/\/www.fda.gov\/media\/186092\/download?attachment."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mito.2017.10.009","article-title":"Mitophagy and the Release of Inflammatory Cytokines","volume":"41","author":"Harris","year":"2018","journal-title":"Mitochondrion"},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Radosavljevic, T., Brankovic, M., Samardzic, J., Djureti\u0107, J., Vukicevic, D., Vucevic, D., and Jakovljevic, V. (2024). Altered Mitochondrial Function in MASLD: Key Features and Promising Therapeutic Approaches. Antioxidants, 13.","DOI":"10.3390\/antiox13080906"},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Velliou, R.I., Giannousi, E., Ralliou, C., Kassi, E., and Chatzigeorgiou, A. (2024). Ex Vivo Tools and Models in MASLD Research. Cells, 13.","DOI":"10.3390\/cells13221827"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.stem.2018.02.011","article-title":"Organs-on-a-chip: A fast track for engineered human tissues in drug development","volume":"22","year":"2018","journal-title":"Cell Stem Cell"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"eaax5516","DOI":"10.1126\/scitranslmed.aax5516","article-title":"Reproducing human and cross-species drug toxicities using a Liver-Chip","volume":"11","author":"Jang","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.30574\/ijsra.2023.8.1.0189","article-title":"Artificial intelligence in multi-omics data integration: Advancing precision medicine, biomarker discovery and genomic-driven disease interventions","volume":"8","author":"Ali","year":"2023","journal-title":"Int. J. Sci. Res. Arch."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3350\/cmh.2021.0127","article-title":"Recent advances in nonalcoholic fatty liver disease metabolomics","volume":"27","author":"Kim","year":"2021","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Meneses, J., Concei\u00e7\u00e3o, F., Van Der Meer, A.D., de Wit, S., and Moreira Teixeira, L. (2024). Guiding organs-on-chips towards applications: A balancing act between integration of advanced technologies and standardization. Front. Lab A Chip Technol., 3.","DOI":"10.3389\/frlct.2024.1376964"},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Mohr, A.E., Ortega-Santos, C.P., Whisner, C.M., Klein-Seetharaman, J., and Jasbi, P. (2024). Navigating challenges and opportunities in multi-omics integration for personalized healthcare. Biomedicines, 12.","DOI":"10.3390\/biomedicines12071496"}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/47\/7\/565\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:12:16Z","timestamp":1760033536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/47\/7\/565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":164,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["cimb47070565"],"URL":"https:\/\/doi.org\/10.3390\/cimb47070565","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]}}}